Camrelizumab vs Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Camrelizumab Versus Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial
Lancet Oncol 2021 Jun 23;[EPub Ahead of Print], Y Yang, S Qu, J Li, C Hu, M Xu, W Li, T Zhou, L Shen, H Wu, J Lang, G Hu, Z Luo, Z Fu, S Qu, W Feng, X Chen, S Lin, W Zhang, X Li, Y Sun, Z Lin, Q Lin, F Lei, J Long, J Hong, X Huang, L Zeng, P Wang, X He, B Zhang, Q Yang, X Zhang, J Zou, W Fang, L ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.